COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges

Anup S. Pathania; Philip Prathipati; Bakrudeen A.A. Abdul; Srinivas Chava; Santharam S. Katta; Subash C. Gupta; Pandu R. Gangula; Manoj K. Pandey; Donald L. Durden; Siddappa N. Byrareddy; Kishore B. Challagundla

doi:10.7150/thno.51471

COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges

Anup S. Pathania, Philip Prathipati, Bakrudeen A.A. Abdul, Srinivas Chava, Santharam S. Katta, Subash C. Gupta, Pandu R. Gangula, Manoj K. Pandey, Donald L. Durden, Siddappa N. Byrareddy, Kishore B. Challagundla

Research output: Contribution to journal › Review article › peer-review

73 Scopus citations

Abstract

The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.

Original language	English (US)
Pages (from-to)	731-753
Number of pages	23
Journal	Theranostics
Volume	11
Issue number	2
DOIs	https://doi.org/10.7150/thno.51471
State	Published - 2020

Keywords

COVID-19
Cancer
Comorbidity
Coronaviruses
Inflammation
SARS-CoV-2

ASJC Scopus subject areas

Medicine (miscellaneous)
Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Access to Document

10.7150/thno.51471

Cite this

@article{48c1e6dcc20c4207aa0a87f967184a34,

title = "COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges",

abstract = "The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.",

keywords = "COVID-19, Cancer, Comorbidity, Coronaviruses, Inflammation, SARS-CoV-2",

author = "Pathania, {Anup S.} and Philip Prathipati and Abdul, {Bakrudeen A.A.} and Srinivas Chava and Katta, {Santharam S.} and Gupta, {Subash C.} and Gangula, {Pandu R.} and Pandey, {Manoj K.} and Durden, {Donald L.} and Byrareddy, {Siddappa N.} and Challagundla, {Kishore B.}",

note = "Publisher Copyright: {\textcopyright} The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.",

year = "2020",

doi = "10.7150/thno.51471",

language = "English (US)",

volume = "11",

pages = "731--753",

journal = "Theranostics",

issn = "1838-7640",

publisher = "Ivyspring International Publisher",

number = "2",

}

TY - JOUR

T1 - COVID-19 and cancer comorbidity

T2 - Therapeutic opportunities and challenges

AU - Pathania, Anup S.

AU - Prathipati, Philip

AU - Abdul, Bakrudeen A.A.

AU - Chava, Srinivas

AU - Katta, Santharam S.

AU - Gupta, Subash C.

AU - Gangula, Pandu R.

AU - Pandey, Manoj K.

AU - Durden, Donald L.

AU - Byrareddy, Siddappa N.

AU - Challagundla, Kishore B.

N1 - Publisher Copyright: © The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PY - 2020

Y1 - 2020

N2 - The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.

AB - The coronavirus disease 2019 (COVID-19) is a viral disease caused by a novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that affects the respiratory system of infected individuals. COVID-19 spreads between humans through respiratory droplets produced when an infected person coughs or sneezes. The COVID-19 outbreak originated in Wuhan, China at the end of 2019. As of 29 Sept 2020, over 235 countries, areas or territories across the globe reported a total of 33,441,919 confirmed cases, and 1,003,497 confirmed deaths due to COVID-19. Individuals of all ages are at risk for infection, but in most cases disease severity is associated with age and pre-existing diseases that compromise immunity, like cancer. Numerous reports suggest that people with cancer can be at higher risk of severe illness and related deaths from COVID-19. Therefore, managing cancer care under this pandemic is challenging and requires a collaborative multidisciplinary approach for optimal care of cancer patients in hospital settings. In this comprehensive review, we discuss the impact of the COVID-19 pandemic on cancer patients, their care, and treatment. Further, this review covers the SARS-CoV-2 pandemic, genome characterization, COVID-19 pathophysiology, and associated signaling pathways in cancer, and the choice of anticancer agents as repurposed drugs for treating COVID-19.

KW - COVID-19

KW - Cancer

KW - Comorbidity

KW - Coronaviruses

KW - Inflammation

KW - SARS-CoV-2

UR - http://www.scopus.com/inward/record.url?scp=85097178593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097178593&partnerID=8YFLogxK

U2 - 10.7150/thno.51471

DO - 10.7150/thno.51471

M3 - Review article

C2 - 33391502

AN - SCOPUS:85097178593

SN - 1838-7640

VL - 11

SP - 731

EP - 753

JO - Theranostics

JF - Theranostics

IS - 2

ER -

COVID-19 and cancer comorbidity: Therapeutic opportunities and challenges

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this